-
Ferring and the Institut Pasteur collaborate in novel IBD drug development project
in Uncategorized onFerring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical…
0 -
Ferring announces European approval of new room temperature stable formulation of PABAL® (carbetocin)
in Uncategorized onFerring announced today that its new room-temperature-stable* formulation of PABAL® (carbetocin) for intravenous (IV) administration…
-
Ferring Pharmaceuticals acquires novel drug delivery technology from CTCBIO Inc.
in Uncategorized onFerring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to…
-
Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy
in Uncategorized onFerring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first…
-
Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
in Uncategorized onFerring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET)…
-
Ferring Pharmaceuticals moves to strengthen growth with appointment of Chief Medical and Chief Scientific officers
in Uncategorized onFerring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer…
-
Launch of MISODEL® (misoprostol)
in TIMELINES onLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
-
Ferring Pharmaceuticals Announces Grand Opening of U.S. Operations Center
in Uncategorized onFerring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new U.S. Operations Center on a 25-acre lot located at 100…
-
New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists
in Uncategorized onNew data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS)…
-
CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval
in Uncategorized onFerring Pharmaceuticals announced today that its CORTIMENT® MMX® (budesonide) treatment for the induction of remission in patients…
Archiwum Autora pulse
Articles by: pulse